Gilead Sciences, Inc. (GILD) To Go Ex-Dividend on June 15th

Gilead Sciences, Inc. (NASDAQ:GILD) announced a quarterly dividend on Wednesday, April 29th. Stockholders of record on Monday, June 15th will be given a dividend of 0.82 per share by the biopharmaceutical company on Monday, June 29th. This represents a c) annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend is Monday, June 15th.

Gilead Sciences has increased its dividend payment by an average of 0.0%annually over the last three years and has increased its dividend annually for the last 10 consecutive years. Gilead Sciences has a payout ratio of 38.5% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Gilead Sciences to earn $9.53 per share next year, which means the company should continue to be able to cover its $3.28 annual dividend with an expected future payout ratio of 34.4%.

Gilead Sciences Stock Down 0.2%

GILD opened at $125.59 on Friday. Gilead Sciences has a 12 month low of $104.46 and a 12 month high of $157.29. The stock has a market capitalization of $155.93 billion, a P/E ratio of 17.11 and a beta of 0.31. The business has a 50 day simple moving average of $133.16 and a 200-day simple moving average of $134.28. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.12. The firm had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.Gilead Sciences’s revenue was up 4.4% on a year-over-year basis. During the same period in the previous year, the firm posted $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, equities analysts anticipate that Gilead Sciences will post -0.79 earnings per share for the current fiscal year.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.